Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have prostate cancer that has been confirmed through laboratory testing of tissue samples
- People whose cancer has been determined eligible for a specific treatment called 177Lu-PSMA-617, either through a special access program or as part of an approved trial
- People whose scans (PET/CT imaging) show that cancer has spread to lymph nodes or soft tissue in a way that allows a guided tissue sample to be taken
- People whose blood platelet count is above 75,000/ul, tested within 14 days before the tissue sample procedure
- People whose blood clotting levels (measured by specific tests called PT/INR and PTT) are within an acceptable range, tested within 14 days before the tissue sample procedure
- People who take blood-thinning medications (such as warfarin or aspirin) may still be considered, provided the treating doctor determines it is safe to pause those medications for one week before the procedure (confirm with trial site)
Who may not be able to join:
- People who have significant bleeding disorders, whether present from birth or developed over time (for example, von Willebrand's disease or conditions affecting blood clotting factors)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Johannes Czernin, UCLA / Jonsson Comprehensive Cancer Center
Phone: 310-794-3421
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with a successful evaluable biopsy with molecular and cellular alterations after radioligand therapy (RLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.